Lara Hathout

Lara Hathout practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Lara Hathout's NPI, 1588005904, was assigned on July 14, 2013. Lara Hathout graduated from University of Montreal Faculty of Medicine in 2008. Lara Hathout holds New Jersey license 25MA09910700.

Lara Hathout's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Lara Hathout also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Lara Hathout's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Lara Hathout is also affiliated with JFK University Medical Center. The medical group on file is University Neuro-Ophthalmology Associates. Dmand AI also links Lara Hathout to 4 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Lara Hathout practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Lara Hathout's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Lara Hathout is board certified in radiation oncology by the American Board of Radiology. Lara Hathout is licensed in New Jersey.

Dmand AI lists bladder cancer radiation, bone cancer radiation, cervical cancer radiation, prostate cancer radiation and uterine cancer radiation among the conditions Lara Hathout treats.

CMS data shows 1,283 Medicare services from Lara Hathout across 11 procedure codes in 2024, for 173 Medicare patients. Medicare paid $87,998 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 173 Medicare patients who saw Lara Hathout in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have cancer, and 75% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Lara Hathout's median patient age at 74, with 44% women.

In 2024, Lara Hathout wrote 85 Medicare Part D claims for 24 patients. 95% of them were for generic drugs. CMS names the drug for 62 of them, across 2 drugs with 11 or more claims each, at $632 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

Lara Hathout accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 60 papers to Lara Hathout, published from 2011 to 2025. 2023 was the busiest year, with 7. The most frequent topics are Brachytherapy, Prostatic Neoplasms and Endometrial Neoplasms. Lara Hathout has published most often in Int J Radiat Oncol Biol Phys. Lara Hathout's most frequent co-authors are Salma K. Jabbour, Emma Charlotte Fields, MD and Kevin V. Albuquerque, MD.

Dmand AI links Lara Hathout to 3 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Vaginal Neoplasms.

CMS Open Payments shows 9 general payments to Lara Hathout from 6 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Siemens Medical Solutions USA, Inc. paid the most, $281.

Lara Hathout graduated from University of Montreal Faculty of Medicine in 2008. Lara Hathout is a member of ASTRO.

Lara Hathout is in network with 10 carriers, including Aetna, Elevance and Horizon Blue Cross Blue Shield of New Jersey. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.